FinancialBuzz.coms latest Buzz on the Street Show: Featuring Our Corporate News Recap on Numinus Announces 2020 Operational Plans to Scale.

Numinus Wellness Inc. (TSX-V: NUMI) is pleased to report its near-term goals to advance our mission to address the universal desire to heal.

Numinus is a Vancouver-based health care company helping to support the universal desire to heal and be well. Numinus believes the societal costs of mental illness, addictions, trauma and unmet human potential are much too high. New approaches and new ways of thinking are required to supplement existing options, including the application of psychedelic assisted therapies when approved by regulators.Numinus Wellnessoperates a stand-alone centre offering patients integrative health solutions to help heal, connect and grow. Psychedelic assisted therapies will be part of this offering but will only be available for treatment once approved by regulators and governing bodies a process Numinus is helping to support.Numinus R&Dis creating partnerships with leading research groups to advance practice and understanding in the space.Numinus Bioscienceis licensed by Health Canada to test, sell, distribute, and eventually conduct research on psychedelic substances. Sustainable cannabis revenue driven by testing operations provides us a foundation for growth.

Recent data indicates that psychedelic products are gaining recognition. Several crucial data points have been observed in recent studies, pointing to potential benefits of such products. For example, according to a recentstudy, a single dose of psilocybin (naturally occurring psychedelic compound) can make symptoms of depression significantly improve. The randomized controlled trial compared single-dose psilocybin with single-dose niacin in conjunction with psychotherapy in participants with cancer-related psychiatric distress. Results suggested that psilocybin-assisted psychotherapy facilitated improvements in psychiatric and existential distress, quality of life, and spiritual well-being up to seven weeks prior to the crossover. At the 6.5-month follow-up, after the crossover, 60-80% of participants continued to meet criteria for clinically significant antidepressant or anxiolytic responses. Following recent studies, and the FDAs decision to approve the first ketamine-based psychedelic medicine from Johnston & Johnston to treat depression, psychedelic products may follow cannabis on a similar path to the legalization and finally breaking free of their established stigma.

The growing awareness of health benefits associated with cannabidiol (CBD) products has pushed the market into mainstream retail. And yet, despite its growth of recent years, it is important to remember that cannabis products are still illegal in the U.S on the federal level. This regulatory obstacle is one of the last remaining difficulties that has been holding the industry back to a significant degree. There is plenty of room for growth here, believes Confident Cannabis VP of Growth & MarketingBrad Bogusaccording to a report byCivilized. CBD is sort of stuck in between prohibition era policies and federal acceptance. We just saw the first cannabis derived FDA approved medication make its way onto the market, which is a CBD medication. Where it goes from here in the world of Big Pharma is hard to say, but the direction will be up, in some velocity. Seniors are more keen to try a CBD product over a THC product, so even on the regular non-pharmaceutical market, CBD will still snag a good portion of untapped market share. International trade of source material is another big advantage of the CBD market, to help it grow.

For more information, please visit: Numinus Wellness Inc.

For more corporate news on Numinus Wellness Inc., check out the Buzz on the Street

About Buzz on the Street: One of FinancialBuzz.coms latest corporate and financial news shows, covering the latest trending stock market news. Buzz on the Street looks to become a leader in corporate video news dissemination. Buzz on the Street is 100% original content, brought to you by Financial Buzz Media.

Read more:
Buzz on the Street Show: Numinus Wellness (TSX-V: NUMI) 2020 Operational Plans to Scale - Financialbuzz.com